Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug’s potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto.
 logo final copy.png)
The Hippocratic Editorial and VT team. Please send your suggestions to [email protected]
Latest posts by Hippocratic Post (see all)
- Manchester University to research the impact of CO on babies - 29th August 2025
- Starvation major cause for A&E admissions - 29th August 2025
- New Monoclonal Antibody Targets Deadly Sepsis - 22nd August 2025
